Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
Vertex Pharmaceuticals (United Kingdom) · Vertex Pharmaceuticals (United States)
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
639
total citations
- FWCI
- 14.37
- Percentile
- 100%
- References
- 25
Citations per year
Authors
8- PMPhilip M. ReaperCorresponding
Vertex Pharmaceuticals (United Kingdom)
- MRMatthew R. Griffiths
Vertex Pharmaceuticals (United States), Vertex Pharmaceuticals (United Kingdom)
- JLJoanna Long
Vertex Pharmaceuticals (United Kingdom), Vertex Pharmaceuticals (United States)
- JCJean‐Damien Charrier
Vertex Pharmaceuticals (United Kingdom), Vertex Pharmaceuticals (United States)
- SMSomhairle MacCormick
Vertex Pharmaceuticals (United States), Vertex Pharmaceuticals (United Kingdom)
Topics & keywords
Topics
Keywords
- DNA damage
- Suppressor
- Cancer cell
- Cancer research
- DNA
- Ionizing radiation
- Cancer
- Kinase
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.